TY - JOUR
T1 - How I treat paediatric relapsed acute myeloid leukaemia
AU - Kaspers, Gertjan
PY - 2014/9
Y1 - 2014/9
N2 - The prognosis of paediatric acute myeloid leukaemia (AML) has improved significantly over the recent decades, but still about one-third of patients relapse. These patients have a relatively poor prognosis, with a probability of long-term survival from relapse of about 35%. This can only be achieved with very intensive chemotherapy and, usually, allogeneic stem cell transplantation, leading to very significant toxicity and even treatment-related mortality. Major improvements in the treatment of paediatric relapsed AML thus are required still, and several possibilities are discussed. In case of a suspected relapse, a comprehensive diagnostic work-up has to be undertaken, because significant changes in the biological features of the AML cells may have occurred between initial diagnosis and relapse. This review discusses many practical issues that one encounters in the treatment of children with relapsed AML. It will also be of interest for those involved in translational research in AML.
AB - The prognosis of paediatric acute myeloid leukaemia (AML) has improved significantly over the recent decades, but still about one-third of patients relapse. These patients have a relatively poor prognosis, with a probability of long-term survival from relapse of about 35%. This can only be achieved with very intensive chemotherapy and, usually, allogeneic stem cell transplantation, leading to very significant toxicity and even treatment-related mortality. Major improvements in the treatment of paediatric relapsed AML thus are required still, and several possibilities are discussed. In case of a suspected relapse, a comprehensive diagnostic work-up has to be undertaken, because significant changes in the biological features of the AML cells may have occurred between initial diagnosis and relapse. This review discusses many practical issues that one encounters in the treatment of children with relapsed AML. It will also be of interest for those involved in translational research in AML.
KW - Allogeneic stem cell transplantation
KW - Minimal residual disease
KW - Personalized therapy
KW - Prognosis
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84906052001&partnerID=8YFLogxK
U2 - 10.1111/bjh.12947
DO - 10.1111/bjh.12947
M3 - Article
C2 - 24837715
AN - SCOPUS:84906052001
SN - 0007-1048
VL - 166
SP - 636
EP - 645
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 5
ER -